IFI16 Enhances Chemosensitivity of Breast Cancer Cells by Inhibiting DNA Damage Response
Authors:
Open Access
- 2 October 2025
- journal article
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 33 (6) , 1015-1023
Abstract
Na-Lee Ka, Ga Young Lim, Seung‑Su Kim and Mi-Ock Lee. Biomolecules & Therapeutics -0001;0:. https://doi.org/10.4062/biomolther.2025.085Keywords
Funding Information
- National Research Foundation of Korea
This publication has 34 references indexed in Scilit:
- Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast CancerClinical Cancer Research, 2010
- Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast CancerClinical Cancer Research, 2010
- Inhibition of ATM kinase activity does not phenocopy ATM protein disruptionCell Cycle, 2010
- IFI16 is an innate immune sensor for intracellular DNANature Immunology, 2010
- Effect of training-sample size and classification difficulty on the accuracy of genomic predictorsBreast Cancer Research, 2010
- Active Role for Nibrin in the Kinetics of Atm ActivationMolecular and Cellular Biology, 2006
- ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 ComplexScience, 2005
- Requirement of the MRN complex for ATM activation by DNA damageThe EMBO Journal, 2003
- The DNA damage response: putting checkpoints in perspectiveNature, 2000